tbuckley/cabot-search huggingface dataset:
A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients
Authors: William K. Hass, J. Donald Easton, Harold P. Adams, William Pryse-Phillips, Basil A. Molony, Sharon Anderson, Barbara Kamm
Journal: New England Journal of Medicine (1989)

We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death. The medications were randomly assigned to 3069 patients with recent transient or mild persistent focal cerebral or retinal ischemia. Follow-up lasted for two to six years. The three-year event rate for nonfatal stroke or death from any cause was 17 percent for ticlopidine and 19 percent for aspirin — a 12 percent risk reduction (95 percent confidence interval, -2 to 26 percent) with ticlopidine (P = 0.048 for cumulative Kaplan–Meier estimates). The rates of fatal and nonfatal stroke at three years were 10 percent for ticlopidine and 13 percent for aspirin — a 21 percent risk reduction (95 percent confidence interval, 4 to 38 percent) with ticlopidine (P = 0.024 for cumulative Kaplan–Meier estimates). Ticlopidine was more effective than aspirin in both sexes. The adverse effects of aspirin included diarrhea (10 percent), rash (5.5 percent), peptic ulceration (3 percent), gastritis (2 percent), and gastrointestinal bleeding (1 percent). With ticlopidine, diarrhea (20 percent), skin rash (14 percent), and severe but reversible neutropenia (<1 percent) were noted. The mean increase in total cholesterol level was 9 percent with ticlopidine and 2 percent with aspirin (P<0.01). The ratios of high-density lipoprotein and low-density lipoprotein to total cholesterol were similar in both treatment groups. We conclude that ticlopidine was somewhat more effective than aspirin in preventing strokes in this population, although the risks of side effects were greater. (N Engl J Med 1989; 321:501–7.)
Abstract 5060: Downregulation of THAP11 by Bcr-Abl promotes CML cell proliferation through c-Myc expression
Authors: Daisuke Yokota, Satoki Nakamura, Tomonari Takemura, Isao Hirano, Takaaki Ono, Kazuyuki Shigeno, Shinya Fujisawa, Kaori Takeshita, Kiyoshi Misawa, Kazunori Ohnishi
Journal: Cancer Research (2010)

Abstract [Background and Purpose] THAP11 (thanatos-associated protein 11) is one of the zinc-dependent, sequence-specific DNA-binding factors, which regulate cell proliferation, apoptosis and cell cycle. It has been reported that THAP11 is ubiquitously expressed in normal tissues and frequently downregulated in several tumors. In CML cells, we found that THAP11 expression was inhibited. We investigated the mechanisms of the suppression of THAP11 and its function in CML cell proliferation. [Methods] The cells used in this study were human CML cell lines, K562 and Meg01 cells. Primary CML cells were obtained from the bone marrow of CML (CP) patients. Human normal mononuclear cells (MNCs) were isolated from bone marrow of healthy volunteers after obtaining informed consents. For analysis of THAP11 mRNA expression, quantitative RT-PCR was performed in all cell lines treated with Abl kinase inhibitors (STI571, AMN107, and BMS354825). For proliferation analysis and the expression of c-Myc in CML cells, MTT assays, western blot and cell cycle analysis were performed in all cell lines transfected with Bcr-Abl siRNA, THAP11 siRNA, or THAP11 cDNA respectively. Moreover, THAP11 expression, c-Myc expression, and the colony counts of CFU-GEMM, CFU-GM, and BFU-E were analyzed in CML stem/progenitor cells transfected with Bcr-Abl siRNA or treated with Abl kinase inhibitors. [Results] In CML cell lines treated with Abl kinase inhibitors or transfected with Bcr-Abl siRNA, the expressions of THAP11 and c-Myc mRNA and protein were significantly increased compared to untreated cells. On the other hand, in CML cells transfected with the THAP11 cDNA, the c-Myc expression was suppressed. The overexpression of THAP11 induced G1 cell cycle arrest through p27 and p21 accumulation, and inhibited the CML cell proliferation. Moreover, in CML stem/progenitor cells obtained from patients with CML, the transfection with Bcr-Abl siRNA or treatment with Abl kinase inhibitors increased the expression of THAP11 mRNA and protein, and decreased the c-Myc expression and the counts of CFU-GEMM, CFU-GM and BFU-E. [Conclusion] Our results demonstrated that the Bcr-Abl suppressed the expression of THAP11, the depletion of THAP11 induced c-Myc expression, and induced the proliferation of CML cells through cell cycle progression. Moreover, induction of THAP11 expression inhibited the proliferation of CML stem/progenitor cells. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5060.
Abstract 2959: p53 as a guardian of genomic junk: A novel role for p53 in epigenetic silencing of retroelements
Authors: Katerina Leonova, Brittany Lipchick, Leonid Brodsky, Elena Komarova, Andrei V. Gudkov
Journal: Cancer Research (2012)

Abstract Demethylating agents have been reported to be more toxic to p53-deficient cells than wild type (WT) cells in several models. To elucidate the mechanism underlying this phenomenon, we performed microarray-based global gene expression profiling of mouse embryo fibroblasts (MEFs) from p53-WT and p53-null mice with or without 5-aza-2′-deoxycytidine (5-aza-dC) treatment. This analysis revealed two major findings. First, all protein-coding transcripts induced by 5-aza-dC treatment in WT cells were highly expressed and irresponsive to the demethylating agent in untreated p53-deficient cells. This observation defines p53 as a major driver of DNA methylation-dependent gene silencing. Second, death of p53-null cells treated with 5-aza-dC is preceded by strong activation of transcription of interferon (IFN)-responsive genes driven by IFNα induction. Since no obvious candidates for the role of IFN-inducing factors were found among the genes represented on the microarray, we carried out high-throughput sequencing (HTS) of the entire transcriptome of p53-WT and p53-null MEFs, treated or untreated with 5-aza-dC. The HTS results revealed striking transcriptional upregulation of numerous genetic elements belonging to various classes of retrotransposons and non-coding RNAs in p53-null, but not in p53-WT cells, treated with 5-aza-dC. We named this phenomenon of massive induction of transcription of retroelements, which are normally repressed by p53, RETROSIS. Retrosis is likely to be the trigger of the observed IFN response and the mediator of toxicity in p53-null cells treated with 5-aza-dC. These findings define a novel role for p53, acting along with DNA methylation, in regulation of epigenetic silencing of the large proportion of the genome that consists of retroelements and suggest a new evolutionary role for this tumor suppressor. The impact of retrosis in tumor cells deficient in p53 and implications of this phenomenon for the tumor suppressor function of p53 will be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2959. doi:1538-7445.AM2012-2959
Abstract 1530: Therapeutic efficacy of cancer stem cell vaccine in an adjuvant setting
Authors: Yangyang Hu, Lin Lu, Alfred E. Chang, Martin Egenti, John Owen, Jeffrey S. Moyer, Mark E.P. Prince, Jianchuan Xia, Shiang Huang, Max S. Wicha, Qiao Li
Journal: Cancer Research (2015)

Abstract The inability to target cancer stem cells (CSC) may be a significant factor contributing to treatment failure. Novel therapeutic strategies are needed to immunologically target CSCs. We have developed a strategy to target the CSC populations in melanoma and squamous cell carcinoma using CSC lysate-pulsed dendritic cells (DC). Using mouse models we demonstrate that DC pulsed with CSCs enriched by virtue of their expression of the CSC marker ALDH (CSC-DC) significantly inhibited local tumor growth, reduced development of pulmonary metastases and prolonged survival in the minimal tumor models. The effect was associated with down regulation of CCR7 and CCR10 in tumor cells and decreased CCL27 and CCL28 expression in lung tissue. CSC-DC vaccine significantly reduced ALDHhigh CSCs. Direct targeting of CSCs was demonstrated by specific binding of IgG produced by ALDHhigh CSC-DC vaccine-primed B cells to ALDHhigh CSCs, resulting in lysis of these target cells in the presence of complement. When administered in the adjuvant setting after surgical excision of the bulk tumor mass, administration of CSC-DC vaccine reduced development of local tumor growth as well as systemic disease and prolonged survival demonstrating the efficacy of this approach. These data suggest that the CSC-DC vaccine approach may be useful in the adjuvant setting where local and systemic relapse are high after surgery. Note: This abstract was not presented at the meeting. Citation Format: Yangyang Hu, Lin Lu, Alfred E. Chang, Martin Egenti, John Owen, Jeffrey S. Moyer, Mark E.P. Prince, Jianchuan Xia, Shiang Huang, Max S. Wicha, Qiao Li. Therapeutic efficacy of cancer stem cell vaccine in an adjuvant setting. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1530. doi:10.1158/1538-7445.AM2015-1530
PREVALENCE AND LONG TERM FOLLOW-UP OF ANOMALOUS CORONARY ARTERIES ORIGINATING FROM OPPOSITE SINUS (ACAOS)
Authors: Negin Nezarat, Yanting Luo, Sirous Darabian, Rine Nakanishi, Anas Alani, Suguru Matsumoto, Jeby Abraham, Fernandez Flores, Matthew Budoff
Journal: Journal of the American College of Cardiology (2015)
SIGNIFICANCE OF MYOCARDIAL TENASCIN-C EXPRESSION IN ASSOCIATION WITH INFILTRATIVE INFLAMMATORY CELLS IN PATIENTS WITH DILATED CARDIOMYOPATHY
Authors: Yasuo Sugano, Takafumi Nakayama, Tetsuro Yokokawa, Toshiyuki Nagai, Hideaki Kanzaki, Taka-aki Matsuyama, Keiko Ohta-Ogo, Yoshihiko Ikeda, Hatsue Ishibashi-Ueda, Takeshi Nakatani, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai
Journal: Journal of the American College of Cardiology (2015)
SAT0243 Endothelial dysfunction reflected by high S-ICAM-1 and VWF levels accelerates coronary atherosclerosis in systemic lupus erythematosus patients
Authors: W. Plazak, K. Gryga, M. Olszowska, A. Mazurek, M. Konieczynska, J. Sznajd, M. Milewski, J. Musial, P. Podolec
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Conventional risk factors of coronary artery disease fail to explain accelerated atherosclerosis in systemic lupus erythematosus (SLE) patients. Clinical and experimental studies shows that soluble intercellular adhesion molecule 1 (sICAM-1) and von Willebrand factor (vWF) levels reflect endothelial damage or dysfunction. <h3>Objectives</h3> This study was conducted to determine the possible influence of endothelial pathology assessed by sICAM-1 and vWF levels on coronary artery calcifications in SLE patients. <h3>Methods</h3> In 60 SLE patients in stable clinical conditions, without a prior history of coronary artery disease, MultiDetector Computed Tomography (MDCT)-based coronary calcium scoring was performed. Laboratory evaluation included serum concentrations of sICAM-1, vWF, C-reactive protein (CRP) and antinuclear antibodies (ANA) titers. <h3>Results</h3> MDCT revealed coronary calcifications in 15 (25%) patients. Calcium scores ranged from 0.3 to 843.2 (median 31,7). No association was found between these scores and conventional coronary artery disease risk factors (obesity, hypertension, tobacco use, hyperlipidaemia, diabetes) nor CRP levels. On the contrary, as compared to patients with calcium score =0, in those with coronary calcifications higher concentrations of sICAM-1 (382.2±328.2 vs. 267.1±62.7, p=0.01), vWF (188.5±87.6 vs. 149.2±52.2, p=0.025) and higher ANA titers (8320±4521 vs. 4668±2717, p=0.03) were found. <h3>Conclusions</h3> Conventional risk factors of coronary artery disease as well as markers of an ongoing inflammation do not show significant association with coronary artery calcifications in SLE patients. Calcified atherosclerotic plaques were observed mainly in patients with elevated levels of sICAM-1, vWF or high ANA titers. The sICAM-1 and vWF levels may serve as a possible risk marker of coronary calcifications and may have a prognostic importance. <h3>Disclosure of Interest</h3> None Declared
Pediatric Presentation of Splenic Marginal Zone Lymphoma on FDG PET/CT Scan
Authors: Alireza Rezaee, Xianfeng Frank Zhao, Vasken Dilsizian, Wengen Chen
Journal: Clinical Nuclear Medicine (2013)

Splenic marginal zone lymphoma (SMZL) comprises about 1% of B-cell lymphomas and typically occurs after the age of 50 years. Pediatric SMZL is very rare, and no FDG PET/CT imaging of the disease has been reported. In the current study, a 4-year-old boy with biopsy-proven SMZL had FDG PET/CT for staging, which showed increased metabolic activity in the spleen and left cervical lymph nodes. A second FDG PET/CT for evaluation of treatment response showed complete resolution of abnormal FDG uptake in the nodes and spleen with decrease in size of the nodes.
Neural reuse implies distributed coding
Authors: Bruce Bridgeman
Journal: Behavioral and Brain Sciences (2010)

Abstract Both distributed coding, with its implication of neural reuse, and more specialized function have been recognized since the beginning of brain science. A controversy over imageless thought threw introspection into disrepute as a scientific method, making more objective methods dominate. It is known in information science that one element, such as a bit in a computer, can participate in coding many independent states; in this commentary, an example is given.
ERCP, Endoscopic Papillotomy and Gallstone Removal by JF B2 Olympus and PFSB 1200 Machida
Authors: A. Montori, G. Viceconte, G. Viceconte, C. Pastorino
Journal: Endoscopy (1978)

ERCP is now used as routine technique and has provided a useful tool for both diagnostic and therapeutic purposes in diseases of the biliary tract. Until now this examination has been performed throughout the world including Italy, using preferably an Olympus JF and JF B2 sideviewing duodenoscope. In addition to 727 ERCP and 55 papillotomies performed using this instrument we have also employed a convertible endoscope Machida PFSB 1200; this fiberscope, with which front and side views are possible, can be used in the study of the oesophagus, stomach, duodenum, cannulation of the papilla of Vater and papillotomy. They results obtained and advantages offered by this instrument will be discussed. Since this endoscope is not usually employed, at least in Europe, for these purposes, we considered it of interest to report on the 251 ERCP and 9 papillotomies including stone removal performed in our department with the Machida PFSB 1200.
Esophageal self-expandable metal stent for an anastomotic colorectal stricture
Authors: A. Mahajan, M. Rothermich, M. Gaidhane, M. Kahaleh
Journal: Endoscopy (2011)

A 49 year-old woman with colonic inertia required total colectomy with ileorectal anastomosis in November 2009. She subsequently developed partial bowel obstruction requiring multiple balloon dilations of a pinpoint anastomotic stricture.
IMPACT OF D-DIMER LEVEL ON MYOCARDIAL INJURY IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A MAGNETIC RESONANCE IMAGING STUDY
Authors: Soonuk Choi, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Jeong Hoon Yang, Jihoon Moon, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2015)
AT-07 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL
Authors: T. S. Armstrong, E. Vera-Bolanos, M. Gilbert, Y. Yuan, K. Wani, J. Wu, A. Omuro, F. Lieberman, H. I. Robins, E. Gerstner, J. Wu, P. Wen, T. Mikkelsen, K. Aldape, T. Mendoza
Journal: Neuro-Oncology (2014)

BACKGROUND: Ependymoma is an uncommon primary CNS tumor in adults, with no standardized treatment at recurrence. Little is known of the symptom burden associated with potential treatments. CERN-0802 combined lapatinib (targets ErbB1, ErbB2) with dose-dense temozolomide for patients with recurrent disease. METHODS: Adults (≥18), KPS ≥70, with centrally confirmed ependymoma participated. Evaluation including imaging and patient reported outcomes measure (PRO:MDASI-Brain or MDASI-Spine) every 2 cycles. The primary endpoint was median progression free survival (PFS); secondary objectives included change in symptom burden. Linear mixed models were fitted to determine if there were significant changes in symptom reports over the treatment course. Analyses were performed for patients with disease progression against those without progression at or before cycle 6. For each model, a symptom was specified as the dependent variable with KPS and treatment cycle as fixed effect factors. Slopes associated with cycles were tabulated and compared. RESULTS: Forty three of fifty patients participated. Overall symptom burden did not significantly worsen during treatment. Baseline mean symptom severity comparisons showed no difference except worse vomiting and vision changes in those who progressed early. Slopes derived from the linear mixed models showed that fatigue, drowsy, dry mouth and spine tumor-related weakness significantly worsened for those who had disease progression at cycle 6 with the majority of symptoms trending for greater severity in those with progression. Although symptom interference was not significantly worse in those who progressed, the trend was in the expected direction. CONCLUSION: This is the first prospective clinical trial that documents the symptoms experienced by patients with recurrent ependymoma who received lapatinib and dose-dense temozolomide. Findings support that there is symptom benefit with disease control associated with treatment response. Monitoring symptom burden has provided an important dimension to the interpretation of results of this clinical trial.
Case 6-1997
Authors: Jonathan P. Gertler, Suzanne B. Keel
Journal: New England Journal of Medicine (1997)

Presentation of CaseA 69-year-old man was admitted to the hospital because of severe abdominal pain.The patient had become anorectic two days before admission. On the next day he had diffuse, dull abdominal pain with nausea and “dry heaves.” That evening he passed a formed brown stool, followed by flatus. He came to the hospital.The patient was a retired boilermaker with a complex medical history of repeated bouts of deep venous thrombosis beginning at the age of 25 years. He also had a history of hypertension, hyperlipidemia, and exposure to asbestos. A stroke and silent anterior and inferior . . .
COMPARISON OF HEALTH AND ECONOMIC OUTCOMES OF NEW ORAL ANTICOAGULANTS FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ATRIAL FIBRILLATION
Authors: Ying Zheng, Sonja V. Sorensen, Ian Menown, Ann-Katrin Gonschior, Eva Kleine, Jutta Heinrich-Nols, Ray Ghouse, Anuraag R. Kansal
Journal: Journal of the American College of Cardiology (2016)
ASSESSMENT OF RIGHT TO LEFT VENTRICULAR INTERDEPENDENCE AT REST AND DURING EXERCISE AND ITS RELATION TO A WORSE FUNCTIONAL CAPACITY AND VENTILATORY EFFICIENCY IN HEART FAILURE
Authors: Greta Generati, Bandera Francesco, Marta Pellegrino, Valentina Labate, Valeria Donghi, Vincenzo Tufaro, Eleonora Alfonzetti, Marco Guazzi
Journal: Journal of the American College of Cardiology (2016)
Abstract P1-11-24: Concurrent and Sequential Bevacizumab and Preoperative Chemotherapy in the Treatment of Locally Advanced Breast Cancer: UAB 0493
Authors: JT Carpenter, A Forero, CI Falkson, LM Nabell, JF De Los Santos, H Krontiras, Y. Li
Journal: Cancer Research (2010)

Abstract From 3/08 through 12/09, 32 patients with HER-2 negative locally advanced breast cancer (LABC) received preoperative chemotherapy (CT) with sequential dose-dense chemotherapy consisting of pegylated liposomal doxorubicin 25 mg/M2 every 2 weeks X 3, paclitaxel 175 mg/M2 every 2 weeks X 3, then cyclophosphamide 600 mg/M2 every 2 weeks X 3, all with concurrent bevacizumab 10 mg/kg every 2 weeks. One patient had progression of disease during treatment and a second developed bone metastasis by the completion of CT. 30/32 had at least 30% shrinkage of tumor clinically. No patient developed cardiac failure. All 31 patients who completed CT had &amp;gt; 55% Left ventricular ejection fraction on echocardiogram before and after CT. The only toxicities greater than grade 2 were skin—grade 3 palmar plantar erythrodysesthesia in 1 and grade 3 hypertension with BP &amp;gt;150/90 in 7 patients. 12 doses of bevacizumab were held due to a blood pressure &amp;gt; 150/90. No proteinuria was seen. 5 patients experienced delayed wound healing after operation. 8/32 pathologic complete responses (pCR) were seen, 2/21 in ER and/or PR positive disease and 6/11 in ER and PR negative disease. 4 additional patients had no invasive tumor remaining in the breast but had ≥1 involved axillary node. Hormonal therapy but no further CT was given postoperatively. 20 patients who had residual invasive tumor and/or involved axillary nodes at operation will receive an additional year of Avastin 15 mg/kg every 3 weeks. 1 patient received only 2 doses, 13 have completed or are receiving bevacizumab, 6 patients have not yet started. None of these 20 has relapsed, with a median followup of 15 months (range 6 to 27 months). 1 who did not receive bevacizumab due to delayed wound healing had progression 6 months after CT. Concurrent bevacizumab with preoperative CT may not influence the rate of pCR; postoperative bevacizumab may decrease recurrence after operation in patients with LABC. Supported through grants from Centocor Ortho Biotech Services &amp; from Genentech Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-24.